Why I’d buy this FTSE 250 flyer alongside AstraZeneca plc

I reckon there is more to come for investors from this pharmaceutical company and from AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Generic pharmaceutical company Hikma Pharmaceuticals (LSE: HIK) released decent-looking interim results today and the shares are up around 7% as I write.

What a fantastic turnaround we are seeing from this firm. Today’s rise adds to what has been a share-price recovery of more than 100% since the stock’s nadir in February. A three-year run of falling earnings has been well and truly broken this year and the market likes it.

Good figures

The figures are rather good. Constant currency revenue in the first half of the year lifted 10% compared to the equivalent period last year, earnings per share shot up a spectacular 57% and net debt fell by 8% to £501m. The directors raised forward guidance for the firm’s Injectables and Generics businesses and reiterated previous guidance for the Branded business. There’s no doubt that the outlook is positive and to underline that point, they pushed the interim dividend just over 9% higher.

Chief executive Siggi Olafson explained in today’s report that Hikma operates in competitive markets and the company doesn’t expect demand to remain as robust for some its injectable products in 2019. “This means we must remain focused on strengthening our customer relationships, improving profitability and advancing our pipeline to ensure future growth.” Hikma has demonstrated its ability to keep ahead of changing dynamics in the markets it serves and could do well from here. I reckon the stock is worth researching with a view to making it a long-term hold alongside pharmaceutical Goliath AstraZeneca (LSE: AZN), which also seems to be emerging from a period of declining earnings.

Emerging growth

The company suffered from falling sales of some of its best-earning products when their patents expired, which opened the market to generic competition from the likes of Hikma Pharmaceuticals. But in the first half of this year, the firm saw strong sales growth from new medicines and the continued strength of the Emerging Markets business.” However, that progress was offset by the firm’s Crestor brand losing exclusivity in Europe and Japan. But looking forward, better days should be coming and the directors expect an improved performance in the second half of this year with increased product sales and news from the pipeline.

Normalised earnings look set to come in more than 50% higher this year and to advance almost 15% in 2019. The stock has moved up around 17% since the beginning of the year, reflecting the improving outlook, but I still think it’s worth considering for a long-term portfolio. The pharmaceutical sector remains attractive to me because of steady demand for medicines, which often leads to reliable cash inflows.

Despite recent challenges, the firm looks set for a period of growth. Chief executive Pascal Soriot said in July’s half-year report that AstraZeneca’s rich pipeline and sharp commercial focus make us confident that we have in place the right conditions for our return to growth this year.” A string of recent pipeline releases bodes well for the future, and I reckon the firm is well worth your research time right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Would Warren Buffett buy BP shares, as oil excitement grows?

Warren Buffett is a big investor in the oil business, and BP's performance has been attracting investor attention in results…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

Here’s how long-term loyalty to UK shares can lead to dazzling returns!

The most successful UK and US share investors buy shares to hold for the long term, as this report shows.

Read more »

Investing Articles

NatWest has just smashed brokers’ dividend forecasts!

After NatWest delivered a Valentine’s Day surprise to investors, our writer thinks the experts may have to raise their dividend…

Read more »

Investing Articles

The NatWest share price slips in early trading despite positive FY 2024 results. What’s the deal?

The NatWest share price is down slightly this morning after the bank released its final results for 2024. Our writer…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

My Legal & General shares have climbed just 7% — so how come I’m sitting on a 20% gain?

Harvey Jones' trading account is showing only a modest return on his Legal & General Shares, but on drilling down…

Read more »

Investing Articles

Prediction: the BP share price could rise in 2025 (or it might fall!)

Following this week’s release of the energy giant’s 2024 results, our writer reviews the prospects for the BP (LSE:BP.) share…

Read more »

many happy international football fans watching tv
Investing Articles

What’s gone wrong with the FTSE 100’s ‘King of Trainers’?

Feeling the pain of a 28% drop in the JD Sports share price over the past three months, our writer…

Read more »

Investing Articles

Is it too late for investors to consider buying these outstanding FTSE 100 shares?

Stephen Wright wonders whether now's the time to consider buying shares in the FTSE 100’s outstanding companies, despite some high…

Read more »